Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine. This inhibition raises acetylcholine levels at the neuromuscular junction, enhancing stimulation of muscle receptors and thereby strengthening muscle contraction.

The exact dose of Mestinon is individualized by the prescribing clinician. Factors such as the severity of the condition, patient weight, renal function, and response to therapy are taken into account, and the prescriber adjusts the regimen accordingly.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified health professional.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mestinon (pyridostigmine) is a reversible, short‑acting cholinesterase inhibitor, whereas drugs such as neostigmine have a similar mechanism but differ in potency and duration. Compared with physostigmine, which crosses the blood‑brain barrier, pyridostigmine primarily acts peripherally, making it the preferred choice for chronic management of myasthenia gravis.

Mestinon tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Mestinon is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Dosing frequency and timing are determined by the prescriber based on the individual’s therapeutic needs.

The most serious adverse events include cholinergic crisis, which can cause severe muscle weakness and respiratory failure, as well as marked bradycardia, bronchospasm, seizures, and severe allergic reactions such as angioedema. Prompt medical attention is required if any of these symptoms develop.

Mestinon should be avoided in patients with known hypersensitivity to pyridostigmine or any excipients, in those with severe renal impairment without dose adjustment, and in individuals taking other potent cholinesterase inhibitors that could lead to excessive cholinergic activity.